Atlas Trials

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Clinical trial NCT04169737 · RECRUITING

Trial details

NCT number
NCT04169737
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Start date
2020-07-29
Primary completion
2028-07-09
Enrollment
168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.